By the time Alzheimer’s disease is diagnosed in most patients, extensive brain damage has already occurred. Palo Alto startup Neurotrack Technologies is developing a predictive test for the disease: Its computer tool that helps predict Alzheimer’s disease three to six years before the first symptoms appear – opening up opportunity for docs to begin early preventative care.
Neurotrack Technologies just raised $1 million in debt, according to a regulatory filing. The company declined to comment on the fundraise, but here’s what it’s generally up to:
The research comes from Emory University; the company spun out in 2012. The startup says its algorithmic analysis can pick up on anomalies in hippocampal function years before the disease has warped the brain’s memory and nerve centers. It’s working with pharma companies to assess potential Alzheimer’s patients in early stage trials – the tool could, after all, help inform how pharma recruits patients into clinical trials for the disease, CEO Ellie Kaplan told MedCity News.
Neurotrack last year raised $2 million in a Series A, though that round was equity – with backing from Peter Thiel’s Founder’s Fund. This one’s all debt.
